| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
|
Lancet
|
2013
|
13.72
|
|
2
|
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.
|
Lancet
|
2011
|
6.91
|
|
3
|
Persisting with prevention: the importance of adherence for HIV prevention.
|
Emerg Themes Epidemiol
|
2008
|
1.71
|
|
4
|
Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand.
|
PLoS One
|
2011
|
1.40
|
|
5
|
Renal function of participants in the Bangkok tenofovir study--Thailand, 2005-2012.
|
Clin Infect Dis
|
2014
|
0.99
|
|
6
|
Knowledge of and opinions on HIV preexposure prophylaxis among front-line service providers at Canadian AIDS service organizations.
|
AIDS Res Hum Retroviruses
|
2013
|
0.95
|
|
7
|
The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs.
|
AIDS
|
2015
|
0.89
|
|
8
|
Risk behaviors and risk factors for HIV infection among participants in the Bangkok tenofovir study, an HIV pre-exposure prophylaxis trial among people who inject drugs.
|
PLoS One
|
2014
|
0.83
|
|
9
|
A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection.
|
Expert Opin Investig Drugs
|
2012
|
0.82
|
|
10
|
Assessment of Oral Fluid HIV Test Performance in an HIV Pre-Exposure Prophylaxis Trial in Bangkok, Thailand.
|
PLoS One
|
2015
|
0.80
|
|
11
|
HIV pre-exposure prophylaxis (PrEP)--a quantitative ethics appraisal.
|
PLoS One
|
2011
|
0.78
|
|
12
|
Role of the pharmacist in pre-exposure chemoprophylaxis (PrEP) therapy for HIV prevention.
|
Pharm Pract (Granada)
|
2009
|
0.78
|
|
13
|
Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study.
|
Lancet HIV
|
2016
|
0.76
|
|
14
|
High Mortality Among Non-HIV-Infected People Who Inject Drugs in Bangkok, Thailand, 2005-2012.
|
Am J Public Health
|
2015
|
0.76
|